Cash, cash equivalents and marketable securities as of September 30, 2023 totaled $758.2. “Cerevel is bringing forward one of the broadest neuroscience pipelines in the industry, with novel approaches to treating challenging diseases, and we remain focused on execution as we head into multiple data readouts in 2024,” said Ron Renaud, president and CEO. “We are well-capitalized, with runway into 2026, and we have a strong team in place to advance our late-stage pipeline of potential new treatments for schizophrenia, epilepsy, and Parkinson’s disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
- Insider Trading: Cerevel (NASDAQ:CERE) Gains on Director’s Massive Buy
- Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
- Cerevel Therapeutics 19.73M share Spot Secondary priced at $22.81
- Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock